Tesamorelin: The FDA-Approved GHRH That Actually Reduces Visceral Fat — My 16-Week Protocol

Most peptides on the market are gray-area research compounds. Tesamorelin is not. It’s the only GHRH analog that holds an actual FDA approval — Egrifta, approved in 2010 for visceral fat reduction in HIV-positive patients on antiretroviral therapy. The mechanism that worked for those patients is the same mechanism that works for any man over 35 carrying gut fat that won’t move on diet alone: a pulsatile growth hormone release from your own pituitary, with a strong preferential bias toward visceral adipose tissue.

I’ve run tesamorelin in three separate 16-week blocks since 2022. I’ve also run sermorelin, CJC-1295 with and without DAC, and ipamorelin stacks for years. Tesamorelin is the only one of the GHRH family where I see visible, measurable visceral fat loss on a DEXA scan that I can attribute to the peptide itself rather than diet drift. This article is what I actually run, what the bloodwork looks like, and where tesamorelin sits in the broader growth hormone strategy I cover across the growth hormone optimization guide and the CJC-1295 + MK-677 + Lantus stack.

What Tesamorelin Actually Is

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH 1-44) with a trans-3-hexenoic acid attached at the N-terminus. That little fatty acid tail is the entire reason it works better than plain sermorelin — it stops the molecule from being chewed up by dipeptidyl peptidase-4 (DPP-4) in serum, so it survives long enough to actually bind GHRH receptors on the anterior pituitary and trigger a pulse of your own growth hormone.

The key word is pulse. Tesamorelin doesn’t flood you with continuous high GH the way pharmaceutical somatropin does. It restores a younger, sharper pulse pattern. Your pituitary still controls the dose. Negative feedback from somatostatin and IGF-1 still applies. That’s why side effect profile in the GHRH family is far cleaner than injecting recombinant GH directly — and it’s also why tesamorelin doesn’t blow up IGF-1 to the 600+ ng/mL range you see on heavier protocols.

Why It’s the Visceral Fat Killer

The reason this peptide owns a niche the others don’t: tesamorelin trial data shows a roughly 15-18% reduction in visceral adipose tissue (VAT) over 26 weeks at 2 mg/day, with subcutaneous fat largely untouched. That preferential VAT reduction is what makes it interesting for any biohacker over 35. Visceral fat is the metabolically dangerous fat — it’s the fat wrapped around your liver, pancreas, and intestines that drives insulin resistance, low testosterone, systemic inflammation, and every cardiometabolic marker that goes sideways with age.

You can’t see VAT in the mirror. You can have shredded abs and still have a fatty liver. The DEXA scan or a simple waist-to-hip measurement is what tells you whether you’re moving the dial. I’ve watched guys in Pattaya — natural, never used a peptide in their lives — drop 4-5 cm off their waist on tesamorelin without changing their training or diet. The mechanism is real and it’s reproducible.

My 16-Week Tesamorelin Protocol

Here’s the actual protocol I run. This is what I do — not medical advice, not a recommendation, just transparency.

Dose: 1 mg subcutaneous, once daily
Timing: Pre-bed, 3+ hours after last meal, on an empty stomach
Site: Rotating subcutaneous — abdomen, thigh, love handle
Reconstitution: Bacteriostatic water, 2 mL into a 10 mg vial = 0.2 mL per 1 mg dose on a U-100 insulin syringe (20 units)
Storage: Reconstituted vial in the fridge, used within 14 days
Duration: 16 weeks on, 8 weeks off

The clinical trial dose is 2 mg. I run 1 mg because I’m not HIV-positive with severe lipodystrophy — I’m a healthy adult chasing diminishing returns. Half the dose with food timing dialed in gives me 80% of the response with much lower cost and side effect burden. If you’re carrying significant central adiposity and want the trial-validated response, 2 mg is the documented effective dose. Below 1 mg the mechanism is real but the response is inconsistent.

Empty stomach matters because spiking insulin blunts GH release through somatostatin. This is the same reason I cover insulin management in detail in the insulin management guide. If you eat a high-carb meal an hour before injecting, you’re paying for the peptide and getting maybe 30% of the pulse you should be getting. Tesamorelin pre-bed on an empty gut, paired with the natural GH pulse that hits 60-90 minutes into deep sleep, is the entire move.

Bloodwork I Run Before, Mid, After

This is non-negotiable. If you’re not running blood work, you’re not biohacking — you’re guessing. Bloodwork is the entire point of my Natty Plus Protocol. For tesamorelin specifically:

Baseline (week -1): IGF-1, fasting glucose, HbA1c, fasting insulin, full lipid panel, ALT/AST, IGFBP-3 if you can get it
Week 8 (mid-cycle): Same panel — looking for IGF-1 climb to mid-200s ng/mL, HbA1c stable, glucose stable, insulin not climbing
Week 16 (end): Same panel + DEXA scan if you can

My typical numbers on 1 mg: IGF-1 climbs from a baseline around 175 ng/mL to roughly 240-260 ng/mL by week 8. Fasting glucose typically goes up 4-6 points. HbA1c moves 0.1-0.2 points. That’s a real metabolic cost — small, but real, and it’s why I cycle off and why I monitor. If your fasting glucose is already above 95 or your HbA1c is above 5.6, dial the dose down or pair tesamorelin with a glucose disposal agent like berberine or metformin. I cover that exact tradeoff in berberine vs metformin.

What 16 Weeks Actually Did to Me

Last block, May through August 2025, here’s what I tracked. Bodyweight basically flat — down 1.4 kg total, which is rounding error over four months. But the body composition shift on the DEXA was real:

Visceral adipose tissue: down ~14% (the headline number)
Android fat (the abdominal/love handle region): down ~9%
Gynoid fat (hips/thighs): essentially unchanged
Lean mass: up about 0.8 kg
Waist circumference: down 3 cm

Sleep got noticeably deeper around week 3. Skin quality improved by week 6 — same effect I get from GHK-Cu, just from a different angle (GHK-Cu acts topically and locally; tesamorelin works through the IGF-1 pathway systemically). Recovery between heavy training sessions shortened by maybe 15-20%. I never noticed the joint aches or carpal tunnel feeling that come with high-dose recombinant HGH because I was nowhere near the IGF-1 levels that produce those.

Side Effects I’ve Seen — Mine and Other Guys’

Honest list:

Injection site reactions — small red welts at injection site for the first 2 weeks. Rotating sites and slow injection fixes this.
Mild water retention in weeks 1-3, then it normalizes
Glucose creep — real, monitorable, manageable
Vivid dreams — your endogenous GH pulse is genuinely sharper, sleep architecture shifts
Increased appetite at the 2 mg dose — much less at 1 mg

I have not seen the carpal tunnel, severe edema, or arrhythmias that show up in HGH abuse cases. The whole point of the GHRH approach is that your own pituitary brakes when feedback says enough. That’s the safety profile advantage — and it’s also why guys chasing 8 IU/day pharma HGH numbers will be disappointed by tesamorelin alone.

Tesamorelin vs the Rest of the GHRH Family

Sermorelin (GRF 1-29): Cheaper, shorter half-life, weaker pulse. Fine entry-level peptide. Wasted on anyone over 35 chasing visceral fat.
CJC-1295 without DAC (mod GRF 1-29): Same 30 minute half-life territory as tesamorelin but a different molecule. Stronger pulse than sermorelin, no visceral fat selectivity in the data.
CJC-1295 with DAC: 6-8 day half-life because of albumin binding. Continuous elevated GH, blunted pulsatility. Different tool, different use case.
Tesamorelin: Trial-validated visceral fat mechanism. The only one with real human RCT data on body composition in non-AIDS populations now too.

Stacking Decisions

Tesamorelin pairs well with ipamorelin (a ghrelin receptor agonist — different mechanism, additive pulse). 100-200 mcg ipamorelin alongside 1 mg tesamorelin pre-bed is a clean stack with no prolactin or cortisol bleed. Don’t combine tesamorelin with CJC-1295 DAC — you’re stacking two GHRH drugs with overlapping mechanism and getting redundancy not synergy. The classic CJC + ipamorelin combo is sermorelin family + ghrelin agonist; tesamorelin + ipamorelin is the upgraded version.

Pairing with BPC-157 for healing or GHK-Cu for skin? No interaction, no problem, run them together. I cover the recovery side of that combination in the BPC-157 + TB-500 + GHK-Cu recovery stack.

Where Tesamorelin Fits in the Bigger Strategy

I don’t think of tesamorelin as a fat loss peptide. I think of it as a visceral repositioning peptide. The mechanism that makes it good for VAT — pulsatile GH that lipolyzes the fat depots most sensitive to growth hormone — is also what makes it a useful piece of the metabolic puzzle as you cross 35, 40, 45. Visceral fat creeps in. Insulin sensitivity slides. Testosterone gets bound up by SHBG climbing alongside aging. Tesamorelin attacks one specific node in that cascade — the one with the highest cardiometabolic payoff per kilo of fat removed.

For a guy with a fasting glucose of 105, an HbA1c of 5.8, a waist that’s drifted from 81 cm to 91 cm over a decade, and a creeping triglyceride number — this is one of the highest-leverage peptide interventions you can run. It’s not a magic bullet. You still need to lift, sleep, and eat like an adult. But for the visceral fat that won’t move on diet alone, tesamorelin is the most evidence-backed tool in the GHRH category, and it’s the one I keep coming back to.

Sourcing, Cost, and the FDA Question

Pharmaceutical Egrifta (Theratechnologies) at the 2 mg dose runs roughly $4,500-5,500 per month in the US — pricing built around HIV-positive insurance reimbursement. Compounded tesamorelin from a 503A pharmacy with a prescribing telehealth provider runs roughly $300-500/month for 1 mg/day, depending on the provider. Research-grade tesamorelin from peptide vendors runs $80-150 per 10 mg vial — same molecule, no medical oversight, no quality assurance, your call.

The FDA has been moving aggressively against compounded peptides since 2023, including an attempt to kill compounded tesamorelin in 2024 — a move I covered in the FDA war on peptides. As of right now, compounded tesamorelin is in a regulatory limbo zone. Stock up while you can if you’ve found a clean source — the regulatory environment can change fast, and Theratechnologies has every incentive to lobby the agency to lock in their monopoly pricing.

The Bottom Line

Tesamorelin is the most rigorously studied peptide in the entire GHRH category. It has FDA-approval-grade trial data backing the visceral fat reduction claim. It does not produce the side effects of recombinant HGH because your own pituitary is still in charge. The cost-to-benefit at 1 mg/day, 16 weeks on, 8 weeks off, with proper bloodwork and a glucose disposal strategy in place, is one of the cleaner peptide interventions you can run after 35.

It’s not for guys chasing 10 lbs of muscle in 12 weeks — that’s a different conversation, run a real anabolic protocol if that’s the goal. It’s not for someone who already has tight glucose control and minimal visceral fat — diminishing returns hit hard. It’s the right tool for the guy with a 90+ cm waist, a fasting glucose creeping up, an HbA1c that’s no longer in the safe zone, and a willingness to inject once a day for four months and run his own labs. That guy gets the most out of this peptide. I’ve been that guy three times now and I’ll be him again.